



#6

1

SEQUENCE LISTING

<110> CLARK, JONATHAN  
LAMONT, ALAN  
WILLIAMS, DAVID

<120> A METHOD FOR MAPPING THE ACTIVE SITES BOUND BY ENZYMES  
THAT COVALENTLY MODIFY SUBSTRATE MOLECULES

<130> 179-54

<140> 10/020,436

<141> 2001-12-18

<150> 09/530,431

<151> 2000-07-26

<150> PCT/GB98/03259

<151> 1998-10-30

<150> GB 9722818.3

<151> 1997-10-30

<160> 19

<170> PatentIn Ver. 2.1

<210> 1

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Consensus  
peptide

<222>

<223> Biotin-epsilon-aminohexanoic acid is linked to the  
aspartic acid residue at position 1

<220>

<221> MOD\_RES

<222> (8)

<223> Norleucine

<400> 1

Asp Glu Glu Asp Tyr Phe Glu Xaa

1

5

<210> 2

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 2  
ccgggatccg ccatgcccat ggacacgagc gtgtat

36

<210> 3  
<211> 57  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 3  
gggggatcct cagtgggtggt ggtgggtggtg ggcacaggca gcctcagcct tctgtgt 57

<210> 4  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 4  
Asp Glu Glu Asp Tyr  
1 5

<210> 5  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 5  
Asp Glu Glu Tyr Phe  
1 5

<210> 6  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 6  
Asp Glu Tyr Glu Phe  
1 5

<210> 7  
<211> 5  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD\_RES

<222> (5)

<223> Norleucine

<400> 7

Asp Tyr Phe Glu Xaa  
1 5

<210> 8

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 8

Asp Glu Glu Asp Tyr  
1 5

<210> 9

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 9

Asp Glu Glu Tyr Asp  
1 5

<210> 10

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 10

Asp Glu Tyr Glu Asp  
1 5

<210> 11

<211> 5

<212> PRT

<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 11  
Asp Tyr Glu Glu Val  
1 5

<210> 12  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<220>  
<221> MOD\_RES  
<222> (5)  
<223> Norleucine

<400> 12  
Tyr Ser Ile Ile Xaa  
1 5

<210> 13  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 13  
Asp Glu Glu Glu Tyr  
1 5

<210> 14  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 14  
Asp Glu Glu Tyr Phe  
1 5

<210> 15  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 15  
Asp Glu Tyr His Asn  
1 5

<210> 16  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 16  
Asp Tyr His Leu Phe  
1 5

<210> 17  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 17  
Tyr Pro Ile Glu Val  
1 5

<210> 18  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 18  
Ser Tyr Phe His Glu  
1 5

<210> 19  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

&lt;400&gt; 19

Lys	Lys	Lys	Lys	Ala	Asp	Glu	Glu	Asp	Tyr	Phe	Ile	Pro	Pro	Ala
1				5					10					15